Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Otezla® (apremilast) – New warning
June 29, 2017 – The FDA approved an update to the Warnings and Precautions section of the Otezla (apremilast) drug label regarding the risk of diarrhea, nausea and vomiting.
